1. Inhibitory effect of troglitazone on TNF-α-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells 
Masayoshi Y Ohta, Yukihiro Nagai, Toshinari Takamura, Erika Nohara, Ken-ichi Kobayashi 
Diabetes Research and Clinical Practice 
Volume 48, Issue 3, Pages (June 2000)
DOI: /S (00)

2. Fig. 1
Time course of TNF-α (500 ng/ml)-induced soluble MCP-1 secretion from human umbilical vein endothelial cells. The results represent the mean±SEM of triplicate values form three separate experiments.
Diabetes Research and Clinical Practice  , DOI: ( /S (00) )

3. Fig. 2
Effect of troglitazone on TNF-α-induced MCP-1 secretions from human umbilical vein endothelial cells (HUVECs). Ten μM troglitazone significantly reduced TNF-α (5, 50 or 500 ng/ml)-stimulated MCP-1 secretions from HUVECs for a period of 24 h. The results represent the mean±SEM of triplicate values from three separate experiments #P<0.05, *P<0.005, **P<0.001 versus TNF-α alone.
Diabetes Research and Clinical Practice  , DOI: ( /S (00) )

4. Fig. 3
Northern blot analysis of MCP-1 mRNA in cytokine-treated human endothelial cells. The presence of 10 μM troglitazone reduced TNF-α-induced MCP-1 mRNA expression. Arrows indicate the relative migration of 28 S and 18 S RNAs run on the same gel. UV transillumination demonstrated equal quantities of RNA applied to ethidium-bromide-stained agarose gel (lower). The MCP-1 mRNA expressions of the samples are: lane 1, control; lane 2, 500 ng/ml TNF-α; lane 3, 10 μM troglitazone alone; lane 4, 500 ng/ml TNF-α+10 μM troglitazone.
Diabetes Research and Clinical Practice  , DOI: ( /S (00) )